현대ADM
Financials
Valuation Metrics
현대ADM's Market Cap is ₩2266B. At end of 2025 it was ₩1282B. Ranked #752 of 2,436 in KR market (top 31%), #328 of 1,649 on KOSDAQ (top 20%), #83 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 226.58B KRW | KR#752/2,436 Sec#83/234 |
| Revenue | 8.75B KRW | KR#2,300/2,436 Sec#181/234 |
| Net Income | -13.04B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 42.49B KRW | KR#2,252/2,436 Sec#207/234 |
| Net Assets | 31.89B KRW | KR#2,146/2,436 Sec#190/234 |
| Employees | 159 | KR#1,266/2,436 Sec#104/234 |
| Value | ||
| P/B | 7.10x | KR#2,298/2,436 Sec#195/234 |
| P/S | 25.89x | KR#2,346/2,436 Sec#189/234 |
| FCF Yield | -2.31% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -40.88% | KR#2,232/2,436 Sec#190/234 |
| ROA | -30.69% | KR#2,306/2,436 Sec#202/234 |
| Op. Margin | -74.20% | KR#2,281/2,436 Sec#166/234 |
| Revenue Growth | -23.52% | KR#2,103/2,436 Sec#190/234 |
| Financial Health | ||
| Debt Ratio | 133.22% | KR#911/2,436 Sec#106/234 |
| Total Debt | 5.00B KRW | KR#1,781/2,436 Sec#170/234 |
| FCF | -5.22B KRW | KR#1,509/2,436 Sec#117/234 |
| Cash | 2.24B KRW | KR#2,222/2,436 Sec#211/234 |
| Current Ratio | 0.60x | KR#2,189/2,436 Sec#208/234 |
| Performance | ||
| 1Y Return | 192.20% | KR#51/2,436 Sec#3/234 |
| 1M Return | -14.98% | KR#2,023/2,436 Sec#200/234 |
| From 52W High | -80.44% | KR#2,358/2,436 Sec#222/234 |
| 1Y MDD | -79.38% | KR#2,282/2,436 Sec#210/234 |
| Trading | ||
| Volume | 1,203,061 shares | KR#116/2,436 Sec#6/234 |
| Foreign Own. | 4.83% | KR#812/2,436 Sec#78/234 |
| Per Share | ||
| EPS | -252 KRW | KR—/2,436 Sec—/234 |
| BPS | 564 KRW | KR#2,381/2,436 Sec#226/234 |
Company Info
Established in 2003, this Contract Research Organization (CRO) was acquired by Hyundai Bioscience in 2024. It holds exclusive rights to drug delivery technology and provides comprehensive services to pharmaceutical companies and bio-ventures, including clinical trial design, monitoring, and data management. The company is developing breast and lung cancer treatments using inorganic material-based drug delivery system technology. It aims to become a global specialized oncology company through digital clinical trials leveraging AI, Big Data, and remote monitoring. Hyundai ADM is headquartered in Jongno-gu, Seoul.